B. Riley Has Strong Forecast for ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at B. Riley boosted their FY2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Thursday, January 2nd. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of $1.00 per share for the year, up from their previous estimate of $0.99. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($3.79) per share.

Other equities analysts have also issued research reports about the company. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Sanford C. Bernstein decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a report on Friday, November 29th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a report on Friday, December 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Finally, Piper Sandler reduced their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Stock Down 1.5 %

Arrowhead Pharmaceuticals stock traded down $0.29 during mid-day trading on Monday, hitting $19.50. The company had a trading volume of 1,462,451 shares, compared to its average volume of 1,255,717. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $39.83. The business has a fifty day moving average of $21.04 and a 200 day moving average of $22.61. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of -3.88 and a beta of 0.97.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Adeoye Y. Olukotun sold 2,850 shares of the business's stock in a transaction on Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the sale, the director now directly owns 36,740 shares of the company's stock, valued at $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Richard Anzalone sold 26,712 shares of the stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $21.24, for a total value of $567,362.88. Following the completion of the transaction, the chief executive officer now owns 3,688,335 shares of the company's stock, valued at $78,340,235.40. This trade represents a 0.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,393 shares of company stock worth $1,172,009 over the last ninety days. 4.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARWR. HighTower Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 11.5% in the third quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company's stock valued at $2,401,000 after purchasing an additional 12,706 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 3.9% during the 2nd quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company's stock worth $231,022,000 after acquiring an additional 333,333 shares during the period. Intech Investment Management LLC acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $659,000. Erste Asset Management GmbH purchased a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at about $924,000. Finally, Millennium Management LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 61.9% in the 2nd quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company's stock valued at $13,755,000 after purchasing an additional 202,280 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.